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Colorectal cancer is the third leading cause of cancer death in
Western communities. At the time of death approximately two-
thirds of patients with colorectal carcinoma will have liver metas-
tases (Welch, 1979). Median survival of untreated patients with
liver metastases ranges from 6 to 10 months, mostly depending on
the number and size of the metastases (Cady, 1983). Resection of
colorectal liver metastases, the only curative treatment to date, is
only applicable in 10% of all patients (Ballantyne, 1993). The
majority of patients will have to rely on other, mainly palliative
treatment modalities, of which none of them have proven to be of
real benefit to the patient with irresectable liver metastases (Bush,
1995). Interstitial photodynamic therapy (PDT) could be an effec-
tive, minimally invasive treatment for patients with a few liver
metastases. PDT is a treatment modality for cancer, in which a
photosensitizing drug (photosensitizer) is administered and subse-
quently illuminated with light of a specific wavelength, matching
an absorption peak of the drug. Upon illumination the photosensi-
tizer becomes activated and reacts with available oxygen, causing
the production of reactive oxygen species, leading to vascular
damage and direct cellular damage (Star et al, 1986; Henderson
and Dougherty, 1992). Light used in PDT treatment can be deliv-
ered selectively to target tissue via optical fibres placed in the
tissue; a treatment called interstitial therapy (Marijnissen et al,
1992). Next to a photochemical reaction, the activated photosensi-
tizer can emit light useful for detection of sensitized tissue (photo-
diagnostics). In vivo fluorescence measurements can be used to
study photosensitizer kinetics non-invasively (Braichotte et al,
1995a).
Clinically, PDT is mainly used for treatment of superficially
located malignancies, such as lung, skin, bladder, oesophagus, and
head and neck cancer (Schuitmaker et al, 1996). It has rarely been
used to treat deep-seated malignancies, like liver metastases. The
use of PDT for liver neoplasms has been limited as most photo-
sensitizers are efficiently accumulated in normal liver tissue, not
leading to selective uptake into malignant tissue. Also, liver tissue,
being a highly pigmented tissue, limits deep penetration of light
and thus treatment volumes. Experimental studies, using first-
generation photosensitizers haematoporphyrin derivative (HpD)
and photofrin, have shown PDT to be capable of inducing tumour
destruction within the liver (Holt et al, 1985; van Hillegersberg et
al, 1992), despite limitations like non-selective uptake and limited
light penetration. New, second-generation photosensitizers could
possibly establish a more selective accumulation in tumour tissue
and, when absorbing at longer wavelength (> 650 nm), could
result in larger volumes of necrosis. In a previously performed
study we used the photosensitizer bacteriochlorin a (BCA), which
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has an absorption maximum at a wavelength of 760 nm (Rovers et
al, 1998). Due to deeper penetration of 760 nm light, we were able
to induce lesions of up to 16 mm in diameter with a single, plain-
cut fibre (diameter 0.4 mm). Although extensive tumour necrosis
was induced by BCA-PDT, islands of viable tumour cells
remained, leading to tumour regrowth in due time. Because of this
we decided to use a potentially more potent photosensitizer, which
is meta-tetra(hydroxyphenyl)chlorin (mTHPC).
mTHPC is a single and pure substance with a high absorption
peak at a wavelength of 652 nm. Recently, mTHPC has shown to
be a very effective photosensitizer in various tumour models and
clinical trials (Ris et al, 1991; Lofgren et al, 1994; Peng et al,
1995; Dilkes et al, 1996; Grosjean et al, 1996; Mlkvy et al, 1997),
with possible preferential uptake in a colon carcinoma in mice
compared to liver concentrations (Whelpton et al, 1995).
Furthermore, mTHPC drug and light doses needed to induce
tumour necrosis are much lower than that of HpD (Berenbaum et
al, 1986).
The aim of this study is to determine mTHPC distribution in
tumour and adjacent liver tissue, via tissue extractions and in vivo
fluorescence measurements, and to assess short-term and long-term
effects of mTHPC-PDT treatment in a rat liver tumour model.
MATERIALS AND METHODS
Animals and tumour model
A total of 66 male Wag/Rij rats (Charles River, Sulzfeld,
Germany), weighing 200–240 g, were used in these experiments.
The animals had free access to food and water. The experiments
were approved by the Animal Welfare Committee of the Leiden
University Medical Centre and the animals received care in accor-
dance with established guidelines.
We used the CC531 cell line, which is a chemically induced
adenocarcinoma of the rat colon, moderately differentiated,
syngeneic and transplantable to Wag/Rij rats, for tumour induction
in the liver (Marquet et al, 1984). Tumour cells were cultured on
RPMI-1640 (Dutch modification) supplemented with 2 mML -gluta-
mine (Gibco, Grand Island, NY, USA), 10% heat inactivated fetal
calf serum, 100 U ml–1 penicillin and 0.1 mg ml–1 streptomycin
sulphate. At laparotomy under inhalation anaesthetics with
halothane, 5 ´ 105 tumour cells were injected subcapsulary into the
liver. For the distribution study, three tumours per rat were induced
(left lateral lobe, upper right lobe and lower right lobe), whereas for
the PDT efficacy studies one tumour per rat was induced (left lateral
lobe). Animals were treated 10 days after tumour cell injection,
when tumours had reached a diameter and thickness of 5- to 7-mm.
Experimental design
In the first part of the study we investigated mTHPC distribution
in tumour and liver tissue at different time intervals after intra-
venous administration. All rats (n = 20) were administered
0.3 mg kg–1 bodyweight mTHPC via the femoral vein, and they
were randomly assigned to four groups. Animals were killed 4, 24,
48 or 72 h after mTHPC administration, after which the liver was
removed and tumours were dissected. Tissue samples were imme-
diately frozen in liquid nitrogen and stored at – 20°C until mTHPC
analysis was performed.
In the second part of the study we measured in vivo fluorescence
levels in tumour and liver tissue after mTHPC administration and,
subsequently, determined the effect of interstitial illumination. All
animals (n = 46) were treated 9 ± 1 days after tumour inoculation.
They were randomly assigned to four treatment groups (n = 10 per
group) and one control group (n = 6). Illumination was performed
at 4, 24, 48 or 72 h after mTHPC administration. In each treatment
group animals received either a dose of 0.1 mg kg–1 or 0.3 mg kg–1
bodyweight mTHPC, and animals in the control group received
either light illumination only or mTHPC administration (0.3 mg
kg–1) only. At laparotomy, prior to light illumination, in vivo fluo-
rescence measurements were performed on liver and tumour tissue.
To measure photosensitizer bleaching, immediately after illumina-
tion fluorescence of tumour tissue was determined. Before treat-
ment, tumour sizes were measured using sliding callipers and
calculated using the formula: 1/4 p R1 R2, where R1 and R2 are
diameters perpendicular to each other.
To qualify short-term effects of PDT treatment, in each treat-
ment group two animals, one of each mTHPC dose, were killed 48
h after illumination (n = 8). Sizes of induced damage were
measured and livers were sectioned for histological examination.
All other animals (n = 32) were allowed to survive for 28 days
after PDT treatment, to assess long-term effects of PDT treatment.
Twenty-eight days after PDT treatment, animals were killed and
the livers were removed. Macroscopically, tumour sizes were
determined, and microscopically the presence of viable tumour
cells was examined to assess tumour response. No viable tumour
cells present was considered to be a complete remission (CR),
whereas presence of viable tumour cells and tumour growth was
considered to be no response (NR) to PDT treatment. To determine
serum levels of aspartate aminotransferase (ASAT) and alanine
aminotransferase (ALAT) as a parameter of liver damage, blood
samples (0.5 ml) were taken by orbital puncture immediately
before and 1, 3, 7, 14, 21 and 28 days after PDT treatment.
Photosensitizer and light delivery
mTHPC was kindly donated by Scotia Pharmaceuticals Ltd
(Guildford, UK). mTHPC (dry, purple crystals) was dissolved in
20% ethanol (96%), 30% polyethylene glycol (PEG) and 50%
water. Animals were kept in subdued light after mTHPC adminis-
tration to avoid possible side-effects. For light illumination, an
argon-pumped dye laser (Spectra Physics Lasers, Mountain View,
CA, USA), with sulphorodamine B as dye, was tuned to emit light
of 652 nm. Laser light was coupled into two quartz fibres with a
core diameter of 0.6 mm, allowing simultaneous illumination of
two animals. At laparotomy the liver was mobilized, tumours were
exposed and a plain cut fibre was positioned directly onto
the tumour surface. Light illumination, with a power output of
100 mW per fibre, was performed for a period of 150 s, delivering
an energy of 15 J to each tumour. Tissue fluence rates were not
measured in this experiment.
Fluorescence measurements in vivo
Fluorescence was measured with a setup previously described by
Sterenborg et al (1996). In short, a halogen (Hg) lamp was used as
light source and the excitation wavelength was 405 nm, selected
through an interference filter (Oriel 56541). Excitation light and
fluorescence were delivered to and from tissue through a bundle of
optical fibres (200 mm) put in contact with the tissue. Fluorescence
was detected at two wavelength ranges: red fluorescence (630–
750 nm) was detected with a long-pass filter (Schott RG 630) anda red-sensitive photomultiplier tube (Hamamatsu R 636-10), and
autofluorescence (550–600 nm) with a 600 nm cut-off glass filter,
a long-pass filter (Schott KV 550) and a green-sensitive photo-
multiplier tube (Hamamatsu IP 128). A standard lock-in technique
was used. A fluorescence ratio (FR) was calculated between the
two detected fluorescence intensities to correct measurements for
changes in excitation light intensity and measurement geometry.
Five measurements were performed per tissue, repositioning the
fibre between each measurement, of which the mean ± standard
error of the mean (s.e.m.) FRs were calculated.
mTHPC concentration determination
mTHPC concentrations were determined using standard extraction
and fluorometry techniques with similarities to the technique as
described by Lilge et al (1997). Briefly, frozen tissue samples
were weighed and mechanically homogenized in 3-ml dimethyl
sulphoxide (DMSO). The homogenate was centrifuged (5000 rpm
for 10 min) and fluorescence in the supernatant was determined
(excitation 420 nm, emission 650 ± 10 nm) using a standard spec-
trofluorometer (Aminco SPF 500) and converted into concentra-
tion by interpolation in a standard curve constructed with known
mTHPC concentrations. After correction for sample weight,
mTHPC concentrations were expressed as mg mg–1 wet tissue. For
each animal the T/L concentration ratio was calculated and per
treatment group the mean (± s.e.m.) T/L-ratio was calculated. Note
that the mean T/L-ratio can be different from the ratio of the mean
tumour and liver tissue concentrations.
Histological examination
Livers were fixated in a 3.6% buffered formalin solution, sliced
through the largest diameter of the tumours, embedded in paraffin
wax and sectioned (4 mm). Sections were stained with haema-
toxylin & eosin (H&E) and examined by a pathologist to detect
presence of viable looking tumour cells and to examine induced
damage to tumour and surrounding liver tissue.
Statistical analysis
All values were expressed as mean ± sem. The unpaired Student’s
t-test was used to evaluate differences in mTHPC concentration,
fluorescence levels and T/L-ratios between the different time
intervals after mTHPC administration and between the two doses
of mTHPC used in the experiments. A P-value of < 0.05 was
considered to be statistically significant.
RESULTS
mTHPC concentration and in vivo fluorescence
measurements
Figure 1 shows that mTHPC concentrations in liver tissue were
highest 4 h after administration, with no significant difference
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Figure 1 mTHPC tissue concentrations determined using ex vivo
extractions. The graph represents the mean (± s.e.m.) mTHPC concentration
in liver and tumour tissue at 4, 24, 48 and 72 h after intravenous
administration of mTHPC. Significantly higher mTHPC concentrations were
detected in tumour tissue than in liver tissue at 24 (P = 0.04) and 48 (P =
0.006) hours after drug administration. Difference in tissue concentrations at
72 h after administration was not significant (P = 0.06). All values are the
mean of five animals, with at least two measurements per tissue per animal
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Figure 2 FR in liver and tumour tissue. FR is the ratio of red fluorescence
(630–750 nm) over the autofluorescence (550–600 nm), to compensate for
tissue optical properties. The graphs represent the mean (± s.e.m.) FR in (A)
liver and (B) tumour tissue 4, 24, 48, and 72 h after administration of 0.1 or
0.3 mg kg–1 mTHPC. In liver tissue there is a significant decline in the FR in
time (4–24 h; P = 0.007 and P = 0.001, 24–48 h; P = 0.003 and P = 0.006,
48–72 h; P = 0.006 and P = 0.007, for 0.1 and 0.3 mg kg–1 mTHPC
respectively). In tumour tissue there was no significant decline in the FR,
except for the FR 48 h after 0.3 mg kg–1 of mTHPC (P = 0.005). FR values
are the mean of five animals per treatment groupPhotodynamic therapy of liver cancer 603
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between liver and tumour tissue concentrations, as illustrated by a
T/L-ratio of 0.9 ± 0.2 (Table 1). Concentrations in tumour tissue
were highest 24 and 48 h after mTHPC administration. mTHPC
concentrations in liver tissue decreased rapidly in time, whereas
mTHPC concentrations in tumour tissue declined slowly, resulting
in a significant difference between liver and tumour mTHPC
concentrations at 24 (P = 0.04) and 48 (P = 0.006) h after adminis-
tration. The mean T/L-ratio increased up to 6.3 at 72 h after
mTHPC administration.
In vivo fluorescence measurements showed comparable results
to extraction data, as illustrated in Figure 2; highest FR in liver
tissue were found 4 h after mTHPC administration with a rapid
decrease in time. From 24 h on, FRs were significantly higher (P <
0.01) in tumour tissue than in liver tissue. The FRs in tumour
tissue remained high, whereas in liver tissue they decreased
rapidly, as clearly indicated by retention of fluorescence (Figure
3). Retention represents the FR as a percentage of FR measured at
4 h after mTHPC administration. Retention in tumour tissue was
93% and 109%, for 0.1 and 0.3 mg kg–1 mTHPC respectively, 24 h
after administration and decreases to 52% and 68% at 72 h,
whereas retention in liver tissue was 25% and 40% at 24 h and
12% for both drug doses at 72 h after administration. The T/L-
ratios of fluorescence data were comparable to concentration
ratios, as shown in Table 1.
In all treatment groups a decrease in tumour FR was seen imme-
diately after illumination (bleaching), with an overall bleaching
percentage between 60% and 75% and there was no significant
difference in percentage of bleaching between the different treat-
ment groups, except for animals illuminated 72 h after injection of
0.1 mg kg–1 mTHPC, where bleaching was only 41% (Figure 4).
Short-term PDT effect
On histological examination sharply demarcated lesions were seen
with extensive necrosis of tumour tissue and some necrosis of
surrounding liver tissue. The largest diameters of PDT-induced
necrosis were measured in the animals treated 4 h after administra-
tion of 0.1 or 0.3 mg kg–1, 10 and 13 mm respectively. PDT at later
time intervals after drug administration resulted in smaller lesions,
ranging from 7 to 9 mm. PDT-induced lesions at later time inter-
vals were more comparable to tumour sizes before treatment and it
seems that damage at these time intervals was more restricted to
the tumour area (Table 2).
Histological examination of tumours treated with PDT showed
in some at random sections the presence of islands of viable
looking tumour cells (Figure 5A). Invasion of granulocytes and
macrophages was seen in all sections, indicating the occurrence of
an acute inflammatory response.
Directly after PDT treatment both serum ASAT and ALAT
levels rose, as represented in Figure 6. Rise in serum enzyme
levels was more profound upon illumination 4 h after mTHPC
administration than upon illumination 48 or 72 h after administra-
tion, indicating that the extent of PDT induced liver damage was
highest at earlier time points between drug administration and illu-
mination. Serum ASAT and ALAT levels normalized within a
week after PDT treatment.
Long-term PDT effect
Assessment of tumour response, 28 days after PDT treatment,
showed complete remissions in 27 out of 31 treated animals
(87%), with only four animals in which PDT treatment had no
effect (Table 3). Tumour sizes of non-responding animals were
comparable to tumour sizes of control animals. Although there
was no significant difference in tumour size before PDT treatment
between different treatment groups, non-responding tumours
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Figure 3 Retention of fluorescence in liver and tumour tissue. This graph
represents FR at 24, 48 and 72 h after mTHPC administration as percentage
of the initial FR at 4 h after administration of 0.1 or 0.3 mg kg–1. Values
represent the mean (± sem) of 5 animals per treatment group. In liver tissue
the FR drops rapidly to 25–40% and eventually 12% at 72 h, whereas tumour
FRs remain high with 52–68% remaining at 72 h after administration
Table 1 Tumour to liver ratio after intravenous injection of mTHPC
T/L-ratio Fluorescence measurements Concentration measurements
Drug–light interval (h)
0.1 mg kg–1 0.3 mg kg–1 0.1 mg kg–1 0.3 mg kg–1
4 0.7 ± 0.1 0.9 ± 0.1 – 0.9 ± 0.2
24 2.5 ± 0.5 2.5 ± 0.3 – 2.6 ± 0.5
48 2.1 ± 0.1 2.9 ± 0.2 – 3.7 ± 0.7
72 3.1 ± 0.5 5.0 ± 0.5 – 6.3 ± 2.7
The mean (± s.e.m.) T/L-ratios were calculated using ex vivo extraction data and in vivo fluorescence data (FR). For in vivo fluorescence
measurements 0.1 and 0.3 mg kg–1 mTHPC was administered, whereas for concentration determinations only 0.3 mg kg–1 mTHPC was
given. All values are the mean of five animals.604 JP Rovers et al
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proved to be significantly larger in size before PDT treatment than
responding tumours, with mean tumour sizes of 37.0 ± 8.5 mm2
and 24.7 ± 9.6 mm2 respectively (P < 0.001).
On histological examination, in case of a CR, only a small
fibrotic lesion was visible on the site where the tumour had been
(Figure 5B). There was a sharp demarcation between healthy and
PDT-damaged tissue, with the occurrence of liver regeneration at
the border; a proliferation of bile ducts was seen as well as prolif-
eration of hepatocytes. In fibrotic lesions different zones could be
identified: in the centre necrotic tissue, surrounded by a rim of
granulocytes and lymphocytes, which was surrounded by a rim of
macrophages (Figure 5C). Non-responding tumours did not show
a difference in morphology compared to non-treated tumours.
DISCUSSION
PDT has the potential of selectively destroying malignant tissue
with minimal damage to healthy tissue. Selectivity of PDT
depends on both photosensitizer localization in tissue and light
administration, which makes it important to determine photosensi-
tizer distribution in target tissue and its surrounding tissue. In case
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Figure 4 Photosensitizer bleaching in tumour tissue. This graph shows the
mean (± s.e.m.) percentage of FR decrease in tumour tissue after
illumination with 652 nm, representing photobleaching of mTHPC. There is
no significant difference in bleaching between treatment groups, with values
ranging from 60 to 72%, except for 72 h after administration of 0.1 mg kg–1,
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Figure 5 (A) Histological section of a PDT-treated tumour, 48 h after illumination. The animal was illuminated with 15 J of 652 nm light 4 h after administration
of 0.3 mg kg–1 of mTHPC. Extensive tumour necrosis (Tn) and necrosis of a rim of normal liver tissue (Ln) is seen in the liver (L). Islands of viable looking
tumour cells (Tv) can be identified within the treated area. B, C Histological section of PDT treated tumours on day 28 after illumination. Animals were treated
with 15 J of laser light 24 (A) or 48 (B) h after administration of 0.3 mg kg–1 of mTHPC. (B) Only a small fibrotic lesion (FI) remained on the site where a tumour
had been, surrounded by normal liver tissue (L). (C) In fibrotic lesions (4) in the liver (5) different zones could be identified: (1) central necrosis, surrounded by
(2) a rim of granulocytes and lymphocytes, which was surrounded by (3) a rim of macrophagesPhotodynamic therapy of liver cancer 605
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of a tumour in a highly vascularized organ as the liver, it will be
difficult to reach selective drug uptake, as most photosensitizers
are efficiently accumulated in liver tissue (Bown et al, 1986;
Bellnier et al, 1989). Only for endogenously generated proto-
porphyrin-IX, after aminolaevulinic acid (ALA) administration,
tumour selectivity has been reported, with tumour to liver ratio of
4:1 (Hillegersberg et al, 1992).
We studied the mTHPC distribution in a transplanted colon adeno-
carcinoma in a rat liver at different times after intravenous adminis-
tration, using ex vivo tissue extractions and in vivo fluorescence
measurements. Both methods showed different mTHPC pharmaco-
kinetics in liver and tumour tissue. In time, mTHPC concentrations in
liver tissue decreased rapidly, whereas mTHPC in tumour tissue
remained high up to 48 h after injection. As previously reported by
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Figure 6 Changes in serum enzyme levels after PDT treatment of liver metastases in rats. The graph shows changes in serum (A) ALAT and (B) ASAT levels
up to seven days after PDT treatment with (- - -) 0.1 or (—) 0.3 mg kg–1 mTHPC. Each point represents the mean of five animals
Table 2 Tumour response after mTHPC-PDT 48 h after light delivery
Area of PDT damage (mm2)a
Time (h)b 0.1 mg kg–1c 0.3 mg kg–1c
4 h 79.3 39.4 93.7 21.6
24 h 28.3 30.1 49.1 26.9
48 h 27.6 15.9 32.0 14.1
72 h 41.0 31.0 27.5 23.9
The area (mm2) of PDT damage, measured 48 hours after PDT treatment,
are given for each drug dose (n = 1) and time interval (n = 1) after mTHPC
administration. aFigures in italics represent tumour sizes (mm2) before PDT
treatment. bTime between drug administration and light delivery (h).
cAdministered dose of mTHPC via the femoral vein.
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Whelpton (Whelpton et al, 1995, 1996), in liver tissue mTHPC
showed an initial rapid decline in the first hours after administration,
followed by a slow decline. We observed similar kinetics in liver
tissue for BCA (Rovers et al, 1998).
In vivo fluorescence measurements have been used as a mini-
mally invasive method to study photosensitizer pharmacokinetics
in animals and humans (Alian et al, 1994; Braichotte et al, 1995b).
However, a problem associated with fluorescence measurements is
the difficulty of obtaining quantitative fluorophore concentrations,
due to varying optical properties of tissues. This makes compar-
ison of fluorescence intensities between tissue types difficult,
especially between dark red liver tissue and pale tumour tissue; as
absorption in liver tissue is higher than in tumour tissue, less light
is transmitted back for fluorescence measurements, possibly
leading to underestimation of fluorophores in liver tissue
compared to those in tumour tissue. Use of the FR corrects
partially for differences in optical properties as fluorescence
values are divided by the autofluorescence, making comparison of
the FR between two tissue types more reliable. Comparison of
fluorescence levels within the same organ is not hindered by
difference in optical properties and thus seems a reliable method to
study in vivo photosensitizer kinetics.
In vivo fluorescence measurements showed similar mTHPC
tissue kinetics as concentration data; FR in liver tissue rapidly
declined in time, to only 12% of the initial value measured at 4 h
after administration, confirming findings of Alian et al (1994).
While liver tissue FR decreased in time, tumour tissue showed no
significant decrease in FRs, leading to significantly higher FR
levels in tumour tissue with a mean T/L-ratio of up to 5.0 ± 0.5 at
72 h after mTHPC administration. A similar increase in T/L-
ratios, up to 6.3 ± 2.7 at 72 h after administration, was seen using
concentration data. In vivo fluorescence measurement showed to
be a useful, non-invasive technique to study drug pharmacoki-
netics and the use of the FR allowed tissue comparisons. Both ex
vivo extractions and in vivo fluorescence measurements showed a
selective retention of mTHPC in tumour tissue, highest 3 days
after drug administration.
FRs in tumour tissue dropped to 25–40% of the initial value after
illumination, which is caused by photosensitizer bleaching.
Providing mTHPC does not produce toxic products on bleaching,
strong bleaching of mTHPC could be advantageous at drug
threshold levels, at which sensitizer levels in normal tissue are low
enough to be totally bleached before inducing toxicity. Some even
propose that precise dosimetry is not essential, when using a highly
bleachable photosensitizer (Potter et al, 1987). Photobleaching
could be used to provide a real-time indication of the PDT effect
upon treatment (Wilson et al, 1997).
PDT with mTHPC was capable of inducing complete tumour
destruction of transplanted tumours within the liver. Although a
zone of liver tissue is damaged around the illuminated tumour,
liver damage is minimal and transient as serum enzyme levels of
ASAT and ALAT normalize within a week after treatment. Normal
tissue damage is limited by: (1) local light administration using
optical fibres; (2) strong absorption of light in liver tissue, limiting
light penetration; and (3) strong bleaching of mTHPC at threshold
levels, which will be the case at longer drug-light intervals.
mTHPC-PDT of liver tumours resulted in an overall CR rate of
87%, with only four out of the 31 treated animals in which tumour
regrowth occurred. Tumour regrowth seemed to be the result of
insufficient tumour illumination, as tumour sizes before PDT treat-
ment were significantly larger in these animals. Using a single,
plain-cut fibre we were able to reach a 100% CR of all tumours
less than 30 mm2 in size. Optimizing tumour illumination, by
using cylindrical diffusers and multiple fibres, will insure a more
homogenous light administration over larger areas, enabling effec-
tive treatment of larger tumour volumes (Mizeret et al, 1996).
A drug dose of 0.1 mg kg–1 mTHPC and a light dose of 15 J was
sufficient to effectively treat liver tumours in the rat model, stating
mTHPC’s potency. Although PDT has proven to be effective in
tumour destruction within the liver using haematoporphyrin deriv-
ative (Holt et al, 1985), photofrin (van Hillegersberg et al, 1992),
pheophorbide a (Nishiwaki et al, 1989) and ALA (Svanberg et al,
1996), much higher light and drug doses were needed. This is
illustrated for photofrin in a liver tumour model in rats: best results
were obtained at a light dose of 800 J cm–1, with complete remis-
sion of four out of six tumours (van Hillegersberg et al, 1992). Our
study clearly indicates that mTHPC is much more potent than
Photofrin, resulting in complete remissions at lower light doses
and, consequently, short treatment times. This makes mTHPC one
of the most potent photosensitizer currently available for treatment
of intrahepatic tumours.
Based on our results, we were not able to determine an optimal
drug–light interval for mTHPC, as treatment at each time point
resulted in complete remissions. Illumination shortly after
mTHPC administration is feasible, as liver damage is minimal and
drug levels in tissue are high. PDT in this case will mainly rely on
vascular damage and less on direct cellular damage. However, as
drug levels in tumour surrounding liver tissue are high, light
delivery, and thus fibre placement, needs to be accurate. A prac-
tical advantage would be that drug injection and light illumination
Table 3 Tumour response after mTHPC-PDT 28 days after light delivery
Complete remissionb No remissionb
Drug-light interval (h) 0.1 mg kg–1 0.3 mg kg–1 0.1 mg kg–1 0.3 mg kg–1
4 3/4 3/4 1/4 1/4
24 4/4 3/3 – –
48 4/4 3/4 – 1/4
72 4/4 3/4 – 1/4
Controla – 3/3
Illumination (= 652 nm, 15 J) was performed 4, 24, 48 and 72 h after intravenous administration of either 0.1 or 0.3 mg kg–1 mTHPC. No
viable tumour cells upon histological examination was considered to be a complete remission (CR), whereas tumour growth was considered
to be no remission (NR). aControl group received mTHPC administration only. bNo. of tumours in complete remission/no. of animals.Photodynamic therapy of liver cancer 607
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could be performed the same day, limiting hospitalization times.
On the other hand, treatment at later time intervals will limit
damage to surrounding liver tissue even further, based on drug-
induced tumour selectivity, making accurate fibre placement less
important. We believe drug selectivity is less important, as damage
to a rim of normal liver tissue is tolerated and even preferred in
treatment of cancerous tissue. Of utmost importance is presence of
enough photosensitizer in tumour tissue to effectively eradicate
tumour cells. Illumination should thus be performed when tumour
tissue concentrations are highest, which is at later time points after
mTHPC administration.
Like many other tissues, liver tissue heals mainly by regenera-
tion after PDT treatment, which is apparent by bile duct prolifera-
tion and hepatocyte proliferation. In case of CR, only a fibrotic
lesion remained at the site where a tumour had been, with liver
regeneration at its border. Different zones could be identified
within the lesion with (1) a central necrotic part, surrounded by
(2) a zone of granulocytes and (3) a zone of macrophages. The
presence of these cells confirm the occurrence of a non-specific
immune response upon PDT treatment, with activation and accu-
mulation of host immune cells (Korbelik and Krosl, 1994; de Vree
et al, 1996). We observed the presence of some viable looking
tumour cells at histological examination 2 days after PDT treat-
ment, though in the same treatment group all animals had CR, 28
days after PDT treatment. An explanation for this could well be
effective destruction of remaining tumour cells by the PDT-elicited
immune response.
In conclusion, mTHPC was retained in tumour tissue, leading to
tumour selectivity in time. Illumination of sensitized tumours
resulted in CR of all tumours less than 30 mm2 in size, without
inducing severe liver damage. Drug doses and light doses used for
mTHPC-PDT were far less than needed with other photosensi-
tizers, making mTHPC the most potent photosensitizer currently
available for treatment of intrahepatic tumours. In patients, light
delivery can be performed percutaneously using laser fibres posi-
tioned in the tumour under ultrasound or computerized tomog-
raphy (CT), as is being done in laser photocoagulation (Amin et al,
1993). Feasibility of interstitial PDT (IPDT) has been demon-
strated by Purkiss et al (1993). The aim of IPDT for liver metas-
tases will at first be palliative treatment of patients with few
irresectable metastases. A clinical study is in progress to assess
safety and effect of IPDT with mTHPC in treatment of colorectal
liver metastases.
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